Efficacy and Safety of Telbivudine as First-Line Therapy in Patients With Compensated Chronic Hepatitis B

Introduction: Chronic hepatitis B (CHB) is a global health problem, with more than 350 million people worldwide infected with hepatitis B virus. Telbivudine, a synthetic thymidine nucleoside analogue, is effective for the treatment of patients with CHB. Methods: This was a non-interventional, observational study conducted in Austria. Treatment of patients with telbivudine (Sebivo®) was in accordance with the actual approved label. Patients were recruited and observed between 28 June 2007 and 22 September 2013. The recommended dose of telbivudine was 600 mg daily. The visits and assessments were performed within…